

REMARKS

Responsive to the restriction requirement set forth in the outstanding Official Action, applicants elect Group I, claims 1-3, 8-10, 15-16 and 19, drawn to a peptide including the sequence 13-39 of the HARP factor or the sequence 65-97 of the HARP factor, a pharmaceutical composition thereof, and a method for preparing a medicament thereof, without traverse.

In reviewing the present specification, applicants noted that the sequence set forth for SEQ ID NO:2, which should correspond to the 13-39 fragment of the HARP factor (SEQ ID NO:1), is erroneously disclosed at page 6 as a 13-40 fragment of the HARP factor. Accordingly, the present specification is amended at page 6, line 22 so as to be consistent with the disclosed and claimed invention relating to the 13-39 fragment of the HARP factor.

Claim 1 is amended. Support for the amendment to claim 1 may be found generally throughout the specification.

Claims 1-19 remain pending in the application.


Pursuant to 37 CFR 1.821-1.825, applicants will provide a new Sequence Listing and disc in a subsequent supplemental amendment.

Favorable action on the merits of the elected Group I is respectfully requested.

The Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 25-0120 for any additional fees required under 37 C.F.R. § 1.16 or under 37 C.F.R. § 1.17.

Respectfully submitted,

YOUNG & THOMPSON



Robert Madsen, Reg. No. 58,543
745 South 23rd Street
Arlington, VA 22202
Telephone (703) 521-2297
Telefax (703) 685-0573
(703) 979-4709

RAM/fb